PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols, so this piece compares approaches within the GLP-1 telehealth category
The diversified GLP-1RAs landscape, which includes acylated peptides, Fc-fusions, depot microspheres, poly-agonist macromolecules, and orally active small molecules, offers versatile opportunities for nanotechnology integration
Its especially appealing for people who have been denied coverage elsewhere or are tired of waiting on prior authorizations
Once released, GLP-1 helps the body to: Stimulate insulin release when blood glucose rises, which helps cells absorb sugar from the bloodstream for energy (1,2)
Metabolic benefits beyond the scale Weight loss is the headline
That is, ePA solves one part of the problem but doesnt eliminate the fundamental issue of authorization itself